Skip to content
Skip to main navigation
Skip to 1st column
Skip to 2nd column
Skip to 2nd column
Aprea AB
Home
Links
Company
Company description
About Aprea
History
Board
Staff
Financial information
Slide show
Career
Research & Development
Research
Development
Contact
Partners
Partnering
News
News
Publications
In the press
Sitemap
Financial information
Owners
Karolinska Development
40.2 %
Industrifonden
28.3 %
Östersjöstiftelsen
11.6 %
Praktikerinvest AB
6.9 %
KD Co-Investment Fund KB 3.6 %
Other owners 9.4 %
Annual Reports
Download as pdf files:
2010
2009
2008
2007
2006
2005
2004
2003
xxxxxxxxxxxxxxxxx
xxx
Certificate of registration
Download as a pdf file:
English version
or
Swedish version
.
xxxxxxxxxxxxxxxxxxxxxx
[ Back ]
At this instant
Aprea strengthens its board, December 22
Aprea announces continuation of Phase I/II-study of APR-246 in patients with leukemia, December 12
Åsa Fransson, new Scientist at Aprea AB, December 12
Aprea secures funding for further development of the anticancer compound APR-246, September 9
Aprea reports completion of the Phase I/II safety study with APR-246 in cancer patients, February 23